# US 2023/0065736 A1 · Oral solid cannabinoid oil composition for treating gastrointestinal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0065736 A1
- Document ID: US20230065736A1
- Status: Published application
- Kind: A1
- Application number: 17/758,315
- Filed: 2021-01-08
- Published: 2023-03-02
- Earliest claimed: 2020-01-08
- Assignees: Societe des Produits Nestle S.A.
- Applicants: SociéTé Des Produits Nestlé S.A.
- Inventors: SYED M. SHAH; FRED HASSAN
- Web page: https://patentgrep.com/patent/US20230065736A1

## CPC

- A61K 9/5026: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/5073: {having two or more different coatings optionally including drug-containing subcoatings}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.

## Claims

### Claim 1

A composition comprising:
an oral multiparticulate dosage form including a plurality of individual particulates, the individual particulates comprising:
(a) a solid core including an effective amount of cannabinoid oil bound in microcrystalline cellulose; and
(b) an enteric coating over the solid core.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the individual particulates are spheroidal, have an average diameter of 0.5 mm to 1.7 mm, and further comprise an enteric coating material and a disintegrant combination that cause the individual particulates to release most of the cannabinoid oil in a subject's duodenum for treating inflammation of the duodenum.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the individual particulates are spheroidal, have an average diameter of 0.5 to 1.7 mm, and are configured to release most of the cannabinoid oil in a jejunum for treating inflammation of the jejunum.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the individual particulates are spheroidal, have an average diameter of 0.5 to 1.7 mm, and are configured to release most of the cannabinoid oil in an ileum for treating inflammation of the ileum.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the individual particulates are spheroidal, have an average diameter of 1.8 to 3 mm, and the dosage form is configured to release the cannabinoid oil for at least 6 hours throughout a subject's intestines.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the cannabinoid oil is bound in microcrystalline cellulose by being stored within microcrystalline cellulose's fibrous network.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cannabinoid oil bound in microcrystalline cellulose is substantially dry.

### Claim 8 (depends on 1)

The composition of claim 1, wherein a ratio of the cannabinoid oil to is MCC 0.5:1 to 1.5:1.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the individual particulates further comprise 10% w/w to 50% w/w cannabinoid oil, 40% w/w to 75% w/w microcrystalline cellulose, 2% w/w to 10% w/w methyl cellulose, and 2% w/w to 35% w/w enteric coating.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the cannabinoid oil includes CBD oil.

### Claim 11

(canceled)

### Claim 12

A method comprising:
wet granulating microcrystalline cellulose and a cannabinoid oil together forming a solid matrix in which the cannabinoid oil is bound in the microcrystalline cellulose; and
combining the solid matrix with at least one pharmaceutical excipient to form an oral pharmaceutical dosage form.

### Claim 13 (depends on 12)

The method of claim 12, wherein wet granulating is performed in a high shear mixer above room temperature for 10 minutes to 20 minutes.

### Claim 14 (depends on 12)

The method of claim 12, wherein the oral pharmaceutical dosage form is a multiparticulate dosage form including a plurality of individual spheroidal particulates having an average diameter of 0.5 mm to 3 mm.

### Claim 15 (depends on 12)

The method of claim 12, wherein the cannabinoid oil is bound in microcrystalline cellulose by being stored within microcrystalline cellulose's fibrous network.

### Claim 16 (depends on 12)

The method of claim 12, wherein the cannabinoid oil bound in microcrystalline cellulose is substantially dry.

### Claim 17 (depends on 12)

The method of claim 12, wherein a ratio of the cannabinoid oil to MCC is 0.5:1 to 1.5:1.

### Claim 18 (depends on 12)

The method of claim 12, wherein the oral pharmaceutical dosage form includes 10% w/w to 50% w/w cannabinoid oil, 40% w/w to 75% w/w microcrystalline cellulose, 2% w/w to 10% w/w methyl cellulose, and 2% w/w to 35% w/w enteric coating.

### Claim 19 (depends on 12)

The method of claim 12, wherein the cannabinoid oil includes CBD oil.

### Claim at position 20

20-31. (canceled)
